Skip to main content
Clinical Trials/NCT02856542
NCT02856542
Completed
Not Applicable

Real-life Evaluation of an Applicator, as a New Mode of Administration of Daivobet® Gel, on Adherence to Treatment and SAtisfaction of Patients With PSOriasis

LEO Pharma1 site in 1 country1,560 target enrollmentMay 23, 2016

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Plaque Psoriasis
Sponsor
LEO Pharma
Enrollment
1560
Locations
1
Primary Endpoint
Morisky Medication Adherence Scale-8
Status
Completed
Last Updated
8 years ago

Overview

Brief Summary

This study aims to describe the patient population being treated and evaluate their treatment adherence and treatment outcomes during treatment of scalp psoriasis with Daivobet® gel Applicator for 4 weeks.

Registry
clinicaltrials.gov
Start Date
May 23, 2016
End Date
June 2017
Last Updated
8 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
LEO Pharma
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Age ≥ 18 years
  • Dermatologist or general practitioner has decided to initiate treatment with Daivobet® gel Applicator

Exclusion Criteria

  • Indication not within the approved labelling in France
  • Contraindication for treatment with calcipotriol or betamethasone dipropionate
  • Informed consent to participate in the study has not been obtained

Outcomes

Primary Outcomes

Morisky Medication Adherence Scale-8

Time Frame: 4 weeks

Degree of adherence to prescribed treatment

Secondary Outcomes

  • Patient opinion on Applicator usability(4 weeks)
  • Patient overall satisfaction(4 weeks)
  • Patient Global Impression of Improvement(4 weeks)
  • Investigator's opinion on the properties of the Applicator(Baseline)

Study Sites (1)

Loading locations...

Similar Trials